First Prospective Study of TKI Ponatinib Shows Benefit in Ph+ALL

The study findings add new insights, but also raise new questions, about the best treatment approach for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Medscape Medical News

source https://www.medscape.com/viewarticle/989065?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?